Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2015 · 10-K
Revenue$159.78M$159.78M+8.0% vs Q4 2014 Net Income$33.35M$33.35M+10.7% vs Q4 2014 EPS Diluted$0.71$0.71+7.6% vs Q4 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,128,000−97.8% Free Cash Flowderived-$10,053,000N/M Margins · derivedGross margin40.8%
Operating margin31.2%+1.1 pt vs Q4 2014
Net margin20.9%+0.5 pt vs Q4 2014
ended Dec 31, 2015 · filed Feb 29, 2016 · 60 d after period end